Our mission: To develop safer and more effective immunotherapies through innovations in drug delivery.
Avidea Technologies is a leader in the development of polymer-based drug delivery systems with immunotherapeutic applications.
Our technology and team are building on more than two decades of pioneering work by our world-class scientific founders and advisors from the National Institutes of Health, the University of Oxford and the Institute for Macromolecular Chemistry. Our founders, advisors and collaborators are experts in the fields of immunology, oncology, vaccines and drug-delivery.
We apply the interdisciplinary expertise of our team to overcome key challenges in drug delivery and advance promising immunotherapies to patients in need.
Avidea Technologies is a leader in the development of polymer-based drug delivery systems with immunotherapeutic applications.
Our technology and team are building on more than two decades of pioneering work by our world-class scientific founders and advisors from the National Institutes of Health, the University of Oxford and the Institute for Macromolecular Chemistry. Our founders, advisors and collaborators are experts in the fields of immunology, oncology, vaccines and drug-delivery.
We apply the interdisciplinary expertise of our team to overcome key challenges in drug delivery and advance promising immunotherapies to patients in need.
Location: United States, Maryland, Baltimore
Employees: 11-50
Investors 1
| Date | Name | Website |
| - | BioHealth ... | biohealthi... |
Mentions in press and media 4
| Date | Title | Description |
| 08.09.2022 | 3 takeaways from Johns Hopkins Technology Ventures’ annual report | Johns Hopkins University is offering a by-the-numbers look into its entrepreneurship ecosystem with the recent release of Johns Hopkins Technology Ventures’ (JHTV) annual report. JHTV works with faculty and students to bring discoveries fro... |
| 16.12.2021 | Johns Hopkins spinout Avidea was acquired by UK company Vaccitech for $40 million | UK biopharmaceutical company Vaccitech has acquired Johns Hopkins spinout Avidea Technologies in a deal valued at $40 million. Vaccitech developed the technology behind the AstraZeneca COVID-19 vaccine in partnership with Oxford University,... |
| 14.06.2021 | Avidea's SNAPvax™ Tolerance Vaccine Program Boosted by SAB Appointments and Encouraging Preclinical Data | BALTIMORE, June 14, 2021 /PRNewswire/ -- Avidea Technologies, Inc. ("Avidea"), a biotechnology company developing 'precision' immunotherapies for cancer and autoimmunity, announced today the appointment of Professor Christopher Je... |
| 01.10.2018 | These 6 startups will pitch at Beta City 2018 | Beta City returns to City Garage in Port Covington on Thursday, October 4, for a celebration of the city’s startup community. Organizers at Betamore announced the companies who will pitch a panel of judges prior to the main event. Starting ... |